Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The patent protection in the drug industry is out of control. Here’s why.

Robert Pearl, MD
Meds
February 21, 2017
Share
Tweet
Share

In the United States, the patent protection process — as it relates to the drug industry — has been distorted by the political system, intense lobbying and large campaign contributions. The result has been pricing contrary to the greater good of the nation.

Patents originated in ancient Greece. This legal protection assumed greater importance in 15th-Century Venice as a means to protect the nation-state’s glassblowing industry. The first patent granted in the United States was in 1790.

Across history, governments created patents for two important purposes: The first was to stimulate interest in research and find solutions to problems that vexed the nation and the world. The second was to promote the broader good of the country. The duration of time designated for exclusive use of the new technology or the approach was intended to be relatively short, with the public gaining the resulting benefits in perpetuity. As such, the granting of a patent was designed to advance not only the interests of its creator but also, equally, the economy and well-being of the nation.

The intent of the patent process and the balance between the dual objectives have been warped over the past decade. Increasingly, drug companies are not investing in R&D proportional to the profits they earn from the drugs they bring to market, despite their protests to the contrary. Instead, many have figured out that it’s simpler and safer, from a financial perspective, to either buy the rights to drugs developed by others and raise the prices many times over, as with Sovaldi. Or they obtain a medication already in existence and, using monopolistic control, raise the price as much as 500 percent or more, as in the case of the EpiPen. As a consequence, the patent protection process now primarily serves the drug companies, most often not on behalf of the American people, but, rather, at their expense.

What patents originally intended

Patent protection was never intended for use in a situation when human life would be endangered through its use. In other areas of society, broad legal prohibitions exist to protect human life and the well-being of citizens. For example, individuals are prohibited from yelling “Fire!” in a theater, and utility monopolies that control all of the electricity for a city are prohibited from price gouging. Patents make sense in a retail or manufacturing context. If you don’t want to purchase Venetian glass, you can decide it’s too expensive. In contrast, if your child is born with a genetic defect, you have no choice but to obtain the medication available for treatment regardless of price.

Patent protection effectively grants the pharmaceutical industry a monopoly, regardless of the human consequences. For a patient with a particular disease and a single solution available in the form of a sole-source drug, allowing exorbitant pricing that prevents access for individuals to the medication runs counter to the expectation of Congress to protect the health of its citizens.

The tension between the individual inventor and the population over what constitutes a reasonable length of protection for intellectual property has played out in countries around the world for centuries. Ultimately, however, a patent is not an intrinsic or Constitutional right, but a conscious choice by governing bodies to grant the exclusive ownership of rights to innovators based, as mentioned, on what’s best for all of the citizens of the nation.

Our nation must achieve a thoughtful balance between the use of patent law to encourage drug companies to develop new medications for diseases that can’t be treated today and the needs of patients to benefit from those drugs without bankrupting either themselves or state and federal budgets. Prices should bear a reasonable and logical relationship to the cost of development in return for protection against competition. And while it’s important that drug developers have a reasonable profit incentive to stimulate innovation, we need as a society to insure that such incentives optimize the right kinds of research and development, and not only the most potentially profitable products. We are nowhere near that optimal point today.

Compounding legal problems

Complicating the problem are two pieces of legislation pushed by big pharma that further distort the current pricing process. First, the prohibition on importing drugs from other countries allows pharmaceutical companies to continue to discriminate on an economic basis against patients in the United States. Second, the federal government is restricted from negotiating prices on behalf of U.S. citizens unlike governments around the rest of the globe, thus guaranteeing Americans will pay more. As a result, our nation uses approximately 40% of the drug products manufactured but funds two-thirds of the profits generated by these global conglomerates.

The need for reforms to deal with drug pricing has not been lost on the president. In his first news conference as president-elect, he highlighted the excessively high drug pricing that exists, and the negative effect it has on U.S. jobs and income.

What’s the answer?

The next big wave of opportunities for the pharmaceutical industry will be the large-molecule biologic medications. These hold promise for the treatment of pain, arthritis, cancer and Alzheimer’s disease. Although these drugs have complex chemical structures, their processes for production are becoming increasingly common. And yet, the drug companies adopt the mindset that the price tags can be $100,000 a year and up. Even a drug like insulin, used by millions of people with diabetes in the United States, is being held hostage by the regulatory and approval process. In the United States today, insulin can cost $100 for a single syringe, while the price in other countries is less than 10% of that.

Drug companies, often deploying individuals and patient groups affected by a disease as their advocates, have pushed for expedited approval for new medications. But if we want to help people and make health care more affordable, we need an even more rapid process for approval of biosimilars and generics.

ADVERTISEMENT

Patents were originally intended to encourage innovators and maximize the greater good. But today that privilege is being abused. Depending on what happens with legislation enacted by the new Congress to modify the Affordable Care Act, this corruption of the patent privilege could harm tens of millions of Americans who today are protected through their health care insurance programs.

The time has come to return to the fundamental intent of the patent process. Patent laws should promote and reward progress, while simultaneously maximizing the good of all. When it comes to the drug industry today, the rewards for pharmaceutical companies exceed the benefits to our nation. Hopefully, Congress and the new president will restore the proper balance.

Robert Pearl is a physician and CEO, Permanente Medical Groups. This article originally appeared in Forbes.

Image credit: Shutterstock.com

Prev

It's time we face it: Fossil fuels are killing us

February 21, 2017 Kevin 11
…
Next

Every doctor needs a moment like this

February 22, 2017 Kevin 4
…

Tagged as: Medications

Post navigation

< Previous Post
It's time we face it: Fossil fuels are killing us
Next Post >
Every doctor needs a moment like this

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by Robert Pearl, MD

  • The emotional toll of a broken health care system

    Robert Pearl, MD
  • Medicare’s cobra effect: How a well-intentioned policy spiraled into a health care crisis

    Robert Pearl, MD
  • Empowering patients: Navigating medical information with AI

    Robert Pearl, MD

Related Posts

  • A drug problem in rural Georgia

    Ashish Advani, PharmD
  • How hospitals can impact generic drug companies

    Mark Kelley, MD
  • Gun control vs. violent criminal control

    Scott Abramson, MD
  • Drug ads are a campaign against physician trust

    Judy Salz, MD
  • Crippling drug costs: the role of insurers

    Janice Boughton, MD
  • The complications of drug regulation

    Julie Craig, MD

More in Meds

  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • Most Popular

  • Past Week

    • Why removing fluoride from water is a public health disaster

      Steven J. Katz, DDS | Conditions
    • When did we start treating our lives like trauma?

      Maureen Gibbons, MD | Physician
    • Mastering medical presentations: Elevating your impact

      Harvey Castro, MD, MBA | Physician
    • Why the pre-med path is pushing future doctors to the brink

      Jordan Williamson, MEd | Education
    • Why what doctors say matters more than you think [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden incentives driving frivolous malpractice lawsuits

      Howard Smith, MD | Physician
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • Bureaucracy over care: How the U.S. health care system lost its way

      Kayvan Haddadan, MD | Physician
  • Recent Posts

    • Why the pre-med path is pushing future doctors to the brink

      Jordan Williamson, MEd | Education
    • Why the fear of being forgotten is stronger than the fear of death [PODCAST]

      The Podcast by KevinMD | Podcast
    • How a rainy walk helped an oncologist rediscover joy and bravery

      Dr. Damane Zehra | Physician
    • How inspiration and family stories shape our most meaningful moments

      Arthur Lazarus, MD, MBA | Physician
    • A day in the life of a WHO public health professional in Meghalaya, India

      Dr. Poulami Mazumder | Physician
    • Why women doctors are still mistaken for nurses

      Emma Fenske, DO | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 5 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why removing fluoride from water is a public health disaster

      Steven J. Katz, DDS | Conditions
    • When did we start treating our lives like trauma?

      Maureen Gibbons, MD | Physician
    • Mastering medical presentations: Elevating your impact

      Harvey Castro, MD, MBA | Physician
    • Why the pre-med path is pushing future doctors to the brink

      Jordan Williamson, MEd | Education
    • Why what doctors say matters more than you think [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden incentives driving frivolous malpractice lawsuits

      Howard Smith, MD | Physician
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • Bureaucracy over care: How the U.S. health care system lost its way

      Kayvan Haddadan, MD | Physician
  • Recent Posts

    • Why the pre-med path is pushing future doctors to the brink

      Jordan Williamson, MEd | Education
    • Why the fear of being forgotten is stronger than the fear of death [PODCAST]

      The Podcast by KevinMD | Podcast
    • How a rainy walk helped an oncologist rediscover joy and bravery

      Dr. Damane Zehra | Physician
    • How inspiration and family stories shape our most meaningful moments

      Arthur Lazarus, MD, MBA | Physician
    • A day in the life of a WHO public health professional in Meghalaya, India

      Dr. Poulami Mazumder | Physician
    • Why women doctors are still mistaken for nurses

      Emma Fenske, DO | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

The patent protection in the drug industry is out of control. Here’s why.
5 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...